Manufacturing Platform & Media Strategy Matters For Mesenchymal Stromal/Stem Cell Production Economics

By Jon Rowley, PhD, Founder & Chief Product Officer and Jon Carson, PhD, Strategic Marketing Manager

Today’s marketed biopharmaceuticals span diverse modalities, disease indications, and addressable patient populations. But all, including cell therapy products, need to scale up from laboratory to commercial production at a key point in their development and thus need clearly defined process economics to achieve critical velocity toward commercial success.

In this White Paper, we’ll explore:

• Why hMSCs embody a key foundational technology platform, providing a robust vehicle for widespread translational development across regenerative medicine applications
• How cell manufacturing science and its wave of process innovation is absolutely required to accompany any prior wave of cell therapy product innovation
• Where hMSC bioproduction scale-up fits on a technology roadmap to fill research, clinical, and commercial needs for our regenerative medicine industry
• Which specific milestones of bioprocess economics are being achieved and contributing to consumer-benefiting economies of scale
• What new strategy to leverage for hMSCs in a world of cell therapies previously pioneered analogously by protein biologics manufacturers
• When we can experience the boost that these efforts will contribute to the whole of biomanufacturing